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Whole-genome sequencing (WGS) can improve assessment of low-frequency and rare variants, particularly in non-European popula-
tions that have been underrepresented in existing genomic studies. The genetic determinants of C-reactive protein (CRP), a biomarker
of chronic inflammation, have been extensively studied, with existing genome-wide association studies (GWASs) conducted in
>200,000 individuals of European ancestry. In order to discover novel loci associated with CRP levels, we examined a multi-ancestry
population (n ¼ 23,279) with WGS (383 coverage) from the Trans-Omics for Precision Medicine (TOPMed) program. We found evi-
dence for eight distinct associations at the CRP locus, including two variants that have not been identified previously (rs11265259 and
rs181704186), both of which are non-coding and more common in individuals of African ancestry (10% and 1% minor allele fre-
quency, respectively, and rare or monomorphic in 1000 Genomes populations of East Asian, South Asian, and European ancestry).
We show that the minor (G) allele of rs181704186 is associated with lower CRP levels and decreased transcriptional activity and protein
binding in vitro, providing a plausible molecular mechanism for this African ancestry-specific signal. The individuals homozygous for
rs181704186-G have a mean CRP level of 0.23 mg/L, in contrast to individuals heterozygous for rs181704186 with mean CRP of
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Whole-genome sequencing (WGS) data are being rapidly
generated in deeply phenotyped cohorts or case-referent
samples of complex disorders by projects such as the
United Kingdom’s 100,000 Genomes Project,1 the Na-
tional Institute of Mental Health’s Whole Genome
Sequencing for Psychiatric Disorders Consortium,2 the Na-
tional Human Genome Research Institute’s Centers for
Common Disease Genomics (CCDG) project (see Web Re-
sources), and the National Heart, Lung, and Blood Insti-
tute’s Trans-Omics for Precision Medicine (TOPMed) Pro-
gram.3 WGS resources can improve interrogation of low-
frequency and rare variation associated with quantitative
traits or clinical outcomes4 compared to genotyping
array-based studies. However, sample sizes remain modest
compared to large-scale genome-wide association studies
(GWASs).
WGS-based analysis may offer particular advantages for
non-European populations currently underrepresented in
GWASs, with 95% of GWAS participants being of Euro-
pean or East Asian ancestry.5 WGS can assess population-
specific variants which are at very low frequency or absent
in large European GWASs, including variants that are often
poorly imputed with standard reference panels and geno-
typing arrays. Current imputation reference panels for
non-European populations (notably 1000 Genomes phase
3, n ¼ 5,008 haplotypes across 26 mostly non-European
populations6) are also much smaller than resources like
the Haplotype Reference Consortium (HRC) for European
populations (n ¼ 64,976 haplotypes),7 making imputation
of low-frequency variants more difficult. Along with dis-
crepancies in imputation reference panel size, many geno-
typing arrays have poor genomic coverage in non-Euro-
pean populations.8 Because WGS assesses the entire
genome of each individual, the limitations of genotyping
arrays and imputation reference panels are easily over-
come, allowing better understanding of the genetic archi-
tecture of complex traits in non-European populations.
Based on previous success in identifying novel coding
low-frequency or population-specific variants for inflam-
matory biomarkers in sequencing-based analyses,9,10 we
evaluated the ability of WGS to identify additional high-
impact non-coding variation for commonly assessed
inflammation biomarker C-reactive protein (CRP).
CRP is an acute-phase protein synthesized in the liver
and is often used as a biomarker for chronic low-grade
inflammation. As such, its relationship to cardiovascular
disease (CVD) has been well established by numerous
epidemiological studies, though current analyses do not
point to a causal relationship with CVD.11,12 CRP has
also been associated with inflammatory disorders,13,14
type 2 diabetes,15 and overall mortality,16 and recent Men-
delian randomization studies have pointed to a potential
causal role in bipolar disorder and schizophrenia.12
CRP demonstrates substantial heritability in family-
based studies (30% in East Asians,17 30%–40% in Euro-
peans,18–20 45% in African Americans21). CRP levels vary
by race/ethnicity group with higher levels observed in in-dividuals of African ancestry compared to European or
East Asian ancestry.22,23 The genetic architecture of CRP
has been investigated in diverse populations by whole-
exome sequencing (WES),10 genome-wide association,24–
26 and fine-mapping studies imputed to various reference
panels27,28 in tens of thousands of samples. Most recently,
the largest GWAS was conducted in up to 204,402 individ-
uals of European ancestry, identifying 58 loci and explain-
ing 7% of the trait variance.12 Some studies have also re-
ported population-specific variants associated with CRP
levels.27 Among reported loci, the locus surrounding the
CRP (MIM: 123260) gene itself on chromosome 1 explains
the largest portion of phenotypic variance (1.4%12), with
multiple distinct signals reported and clear evidence of
allelic heterogeneity across populations.27,28 For example,
using approximate conditional analysis, the most recent
European GWAS analysis reported 13 signals at the CRP lo-
cus (including rs149520992, an intergenic variant with a
minor allele frequency [MAF] of 1% in Europeans and
rare in other populations),12 and four distinct signals
(shared across ancestry groups) were reported in the
multi-ethnic fine-mapping effort from the Population Ar-
chitecture using Genomics and Epidemiology (PAGE)
study.28 African-specific variant rs726640 or variants in
linkage disequilibrium (LD) with it have also been reported
in several previous studies.26,27,29
Using data from the NHLBI TOPMed WGS project, we
sought to investigate the additional value of WGS (beyond
whole-exome sequencing and imputed GWAS) for single-
variant analysis in a set of 23,279 individuals predomi-
nantly of self-reported European, African American, East
Asian, and Hispanic/Latino ancestry with measured CRP
levels (Table S1). We identified association with CRP levels
at eight known loci (CRP, APOE [MIM: 107741], HNF1A
[MIM: 142410], LEPR [MIM: 601007], GCKR [MIM:
600842], IL6R [MIM: 147880], IL1F10 [MIM: 615296],
and NLRP3 [MIM: 606416]) with p < 1 3 109 in an
ancestry-pooled genome-wide single-variant analysis (Ta-
ble 1, Figure S1). We also examined these eight CRP-associ-
ated loci separately in African American (n ¼ 6,545) and
European American (n ¼ 15,065) participants (Table S2).
In the European American analysis, at least one variant
at each locus met the locus-wide significance threshold
for association with CRP levels with the exception of the
NLRP3 locus. The African American analysis also demon-
strated at least one locus-wide significant variant at all
loci except GCKR and LEPR.
We performed stepwise conditional analyses at each of
the eight loci by conditioning on the lead variant at each
locus and then sequentially conditioning on each new
lead variant until no variants met our locus-wide signifi-
cance thresholds (Table 1). Stepwise conditional analyses
were performed in ancestry pooled and stratified (self-re-
ported European American- and African American-spe-
cific) analyses. We identified two conditionally distinct sig-
nals at HNF1A and eight at the CRP locus (Table 2, Figures
1, S2, and S3). The presence of multiple association signals
Table 1. Eight Loci Significantly Associated (p < 1 3 109) with C-Reactive Protein Levels in TOPMed
Locus
Lead





















LEPR rs7516341 intronic 1.9E19 0.09 C 0.43 0.54 0.37 rs72683129 4.7E05 4.7E06 1
IL6R rs4129267 intronic 5.0E12 0.07 T 0.33 0.14 0.40 rs149417774 2.7E04 6.3E06 1
CRP rs7551731 intergenic 1.1E65 0.18 C 0.30 0.22 0.33 rs73024795 1.2E42 2.4E06 8




1.9E13 0.08 C 0.66 0.85 0.58 rs183628627 4.7E04 6.7E06 1
IL1F10 rs6734238 intergenic 8.4E12 0.07 G 0.41 0.45 0.41 rs148498391 4.1E04 6.2E06 1




1.1E65 0.22 C 0.15 0.21 0.13 rs186472069 1.6E05 4.7E06 1
Significance threshold for identification of second signals calculated as p ¼ (0.05/tested variants). EAF, effect allele frequency, for those in TOPMed CRP analysis.at both CRP and HNF1A has been reported in previous
studies, with at least two signals identified at both loci
in a recent multi-ethnic fine-mapping effort (four signals
atCRP, two signals atHNF1A)28 and in the largest European
meta-analysis (13 approximate conditional signals at
CRP and 2 at HNF1A).12 The eight identified signals at
the CRP locus include low-frequency, exonic variants
(rs1800947 [p.Leu184Leu] and rs553202904, a noncoding
proxy for rs77832441 [p.Thr59Met]) and noncoding
variants with much higher MAF in African ancestry indi-
viduals. These African American-driven signals include
both known (rs73024795) and previously unreported
(rs11265259, rs181704186) associations. In an unrelated
subset (n ¼ 17,371), these eight conditionally distinct
signals explained 4.2% of variance in natural log trans-
formed CRP (2.6% in European Americans, 6.0% in African
Americans). When performing stepwise conditional ana-
lyses at the CRP locus separately by ancestry, five condi-
tionally distinct signals were identified in African Ameri-
cans alone and four conditionally distinct signals were
identified in European Americans. Based on these results
and with consideration of population-specific allele fre-
quencies, four signals at CRP were driven primarily by
African American individuals (rs73024795, rs11265259,
rs181704186, rs2211321) and two by European Americans
(rs553202904, rs12734907) (Table S3). The other two sig-
nals (rs7551731 and rs1800947) were shared between Afri-
can Americans and European Americans.
To determine whether the association signals we
observed at the CRP or HNF1A loci were tagging previously
reported associations, we performed a separate conditional
analysis by which we adjusted for all variants associated
with CRP levels at the CRP or HNF1A loci in prior GWAS,
fine-mapping, or exome-sequencing efforts (Tables S4
and S5). In this analysis, two African American-driven
signals at CRP remained locus-wide significant includingrs11265259 (signal ‘‘E’’; b¼0.32, p¼ 7.33 1018; African
American MAF ¼ 0.10) and rs181704186 (signal ‘‘H’’;
b ¼ 0.46, p ¼ 3.0 3 107; African American MAF ¼
0.01); both are rare or monomorphic in other ancestry
populations, with no copies of the minor allele for either
variant found in 1000 Genomes European, East Asian, or
South Asian populations. We also note the unusually
large effect size for rs181704186, with major allele homo-
zygotes having mean CRP levels of 4.11 mg/L (similar to
the overall TOPMed mean of 4.10 mg/L), heterozygotes,
2.97 mg/L, and minor allele homozygotes, 0.23 mg/L,
respectively (Figure 2A). By contrast, the more common
variant, rs11265259, has mean CRP levels of 4.10, 4.36,
and 3.04 mg/L, respectively. LD in African Americans
from TOPMed between rs11265259 and rs181704186
and known signals is listed in Table S6. After adjusting
for known variants at the HNF1A locus (Table S5), both as-
sociation signals were attenuated below the locus-wide sig-
nificance threshold. We thus carried forward the two
conditionally distinct CRP signals, and not the secondary
signal at HNF1A, for further follow-up.
As both remaining CRP variant associations appeared to
be distinct from any previously identified CRP locus
variant association, we attempted to replicate these two
signals using CRP measurements in African American
women from the Women’s Health Initiative (WHI) study
(n ¼ 7,108). The WHI participants had genotype data
from an Affymetrix 6.0 array imputed to the TOPMed refer-
ence panel (freeze 5b, Michigan Imputation Server) but
were not whole genome sequenced through TOPMed at
the time of freeze 5b’s release. Both variants were locus-
wide significant (using the same p ¼ 2.47 3 106 locus-
wide threshold used in our TOPMed analysis in Table 2)
in our independent WHI replication sample of African
Americans (Table S7, rs11265259, p ¼ 6.1 3 109,
rs181704186, p ¼ 9.2 3 1011) with consistent direction
Table 2. Eight Conditionally Distinct Signals Associated with C-Reactive Protein Were Identified at the CRP Locus in TOPMed






















A rs7551731 intergenic 0.18 1.1E65 C 0.30 0.22 0.33 0.20 0.31 –
B rs73024795 intergenic 0.36 5.0E54 T 0.05 0.16 4.98E04 0.18 N/A 1.2E42
C rs2211321 intergenic 0.02 0.05 C 0.70 0.65 0.71 0.64 0.71 3.1E27
D rs553202904a intergenic 0.70 1.4E12 G 0.002 3.82E-04 0.003 N/A 0.003 8.8E17
E rs11265259 intergenic 0.18 8.9E09 C 0.03 0.09 4.31E04 0.10 N/A 9.3E12
F rs1800947 synonymous,
p.Leu184Leu
0.24 5.8E26 G 0.05 0.01 0.06 0.002 0.05 9.2E09
G rs12734907 intergenic 0.08 1.5E12 T 0.26 0.08 0.34 0.02 0.37 7.9E10
H rs181704186 intergenic 0.61 3.9E12 G 0.003 0.009 9.96E05 0.01 N/A 1.0E07
Abbreviations: AFR, African; EUR, European; N/A, not applicable (monomorphic). Letters correspond to the signals displayed in the LocusZoom plot in Figure 1.
Beta, p value, and overall effect allele frequency are from TOPMed pooled ancestry analysis. EAF, effect allele frequency, for those in TOPMed CRP analysis.
aProxy variant is missense, Thr59Met (r2 ¼ 0.98 in analyzed TOPMed samples)of effect. This remained true when conditioning on all
known variants from prior GWASs and exome-sequencing
studies in Table S4 (rs11265259, p ¼ 8.7 3 1012,
rs181704186, p ¼ 9.7 3 106). These replication results
in WHI provide evidence to the validity of these variants
and show the utility of the TOPMed reference panel for
imputation in non-European ancestry individuals.
We performed several in silico analyses to further charac-
terize the putative functional regulatory mechanisms
of these two variants. Both rs11265259 (located 6 kb
downstream of CRP, signal E) and rs181704186 (located
37 kb upstream of CRP, signal H) have high Genomic
Evolutionary Rate Profiling (GERP)31 scores (7.08 for
rs11265259, 7.45 for rs181704186), indicating sequence
conservation across species. In addition, both variants
are located in predicted enhancer regions based on
ChromHMM32 models in liver (Figures 2B and S4),
where CRP is produced. Neither is in strong LD (defined
as r2 > 0.8) with any other variant sequenced in the
TOPMed African American samples. Integrated functional
annotation scores from FUN-LDA comparing all Roadmap
Epigenomics project tissues were highest in adult liver
for both variants (Table S8a), suggesting that liver is a likely
tissue in which these variants play a functional role. The
annotation score for rs181704186was 1.0 in liver, the high-
est possible score. The highest score for rs11265259 was
more modest (0.0746), suggesting weaker evidence of
enhancer function for this variant. Concordant with these
results, our cross-tissue annotation principal components
analysis (see Supplemental Material and Methods) found
that both rs181704186 and rs11265259 were in the top
10% for conservation (scores of 18.8 and 16.3, respec-
tively), with rs181704186 also having high epigenetics
and transcription factor binding scores (Table S8b). Neither
CRP locus variant E nor H was colocalized with eQTLs from
any tissue available in GTEx,33 whole blood (eQTLGen
browser34), or in a recent large adult liver eQTL analysis.35Curiously, however, the latter liver eQTL mega-analysis
identified no cis-eQTL for CRP, despite the very high
expression of CRP in the liver.35 We do note, however,
that existing eQTL datasets that include some African
Americans (such as GTEx) are fairly small; greater sample
sizes and increased genetic diversity of included partici-
pants are needed to better explore eQTL effects for ancestry
specific or low frequency variants like rs181704186 and
rs11265259. However, GeneHancer36 did link the enhancer
region containing rs181704186 to the CRP gene (‘‘elite’’
enhancer-gene connection [interaction confidence score
10.61], reflecting both a high-likelihood enhancer and
strong enhancer-gene link). In summary, rs181704186 in
particular had strong functional annotation scores in a rele-
vant tissue for CRP levels (liver), as well as a large effect size,
making it an attractive candidate for functional follow-up.
Finally, because we observed multiple independent sig-
nals at the CRP locus, we attempted to jointly model these
effects with the FINEMAP statistical fine-mapping
approach. We ran FINEMAP separately on the African
American (AA) and European American (EA) samples,
assuming a maximum of 5 causal variants in AAs and 4
causal variants in EAs (based on the results from the
ancestry-specific conditional analyses). The FINEMAP
method identified 7 variants in the 95% credible set in
AAs (see Table S9 for all variants in the credible sets,
including AA conditional analysis lead rs11265259) and
26 variants in EAs, including conditional analysis lead
variants rs2211320 and rs1800947. Interestingly, while
rs11265259 was included in the 95% credible set in AAs,
rs181704186 was not (r2 < 0.03 with all 7 credible set var-
iants). Nevertheless, we nominated the rs181704186
variant for experimental follow up based on the prepon-
derance of annotation-based evidence detailed above.
We performed further in vitro functional assays to char-
acterize the regulatory role of rs181704186. We cloned a
1141-bp element designed to capture the surrounding
Figure 1. Eight Conditionally Distinct Sig-
nals Associated with C-Reactive Protein
Were Identified at the CRP Locus in
TOPMed
LocusZoom plot of log10(p value) versus
genomic location for all distinct signals at
the CRP locus. Letters correspond to the
list of conditionally distinct signals in Table
2. The lead variant for each conditionally
distinct signal is indicated with a diamond,
with other variants in linkage disequilib-
rium r2 > 0.2 indicated in the colors used
for each letter label and displayed on the
legend at right, each with a different shape
(for example, variants in close linkage
disequilibrium with signal A (rs7551731)
are displayed as red circles). Linkage disequi-
librium is calculated using the same
TOPMed samples included in our pooled
ancestry C-reactive protein analyses.regions of accessible chromatin and of cross-species con-
servation and containing each allele into a luciferase re-
porter vector in both orientations with respect to a mini-
mal promoter (Table S10). Allele-specific clones of the
reporter vector were transfected into the HepG2 hepato-
cyte/liver carcinoma cell line. Consistent with the GWAS
direction of effect, the G allele associated with lower CRP
levels was also associated with lower transcriptional activ-
ity in both the forward and reverse orientations (Figures 2C
and S5A) than the A allele. In vivo, this likely reflects lower
transcription of CRP, based on proximity and the Gene-
Hancer links between this enhancer and the CRP transcrip-
tion start site.36 The cloned regulatory element appears to
be a repressor, as the levels of transcriptional activity are
lower than empty vector controls (Figure 2C).
We next performed an electrophoretic mobility shift
assay (EMSA) to test the alleles of rs181704186 for
differences in transcription factor binding (Figures 2E
and S5B–S5D). We observed an allele-specific band at
rs181704186-A (as indicated with an arrow; comparing
lane 2 versus 7) that is competed away by a 403 excess
of a probe containing the A allele (lane 3), but unaf-
fected by probes containing the G allele (lane 4). The
rs181704186 variant overlaps a CCAAT Enhancer Binding
Protein Beta (CEBPB) binding site in ENCODE ChIP-seq
experiments from HepG2 and HeLa cells, along with
several other transcription factor binding proteins
(Figure 2B). The rs181704186-G allele is predicted to
disrupt the CEBPB motif, changing the position weight
matrix log of the odds score from 14.8 to 2.917,18
(Figure 2D). CEBPB is a transcription factor known to be
important for production of CRP in liver37,38 and a strong
candidate for contributing to the observed allelic differ-
ences in transcriptional activity. We attempted to super-
shift the EMSA DNA-protein complexes with antibodies
to CEBPB. Incubation with an antibody targeting CEBPB
showed a weaker band, which may represent a partiallydisrupted the A-allele-specific protein-DNA complex (lane
5). These allele-specific differences in protein binding are
concordant with the transcriptional reporter assay and
are suggestive that disruption of transcription factor bind-
ing at least partially mediates these regulatory effects,
although further evidence is needed to determine the
role of CEBPB and/or other transcription factors.
Using data from the TOPMed program, we report two
low-frequency, population-specific variants that are asso-
ciated with circulating CRP levels. Prior studies of geno-
types imputed to the 1000 Genomes reference panels
have not detected these associations. The best powered
CRP GWAS to date included only individuals of European
ancestry,12 a population for which these variants would
not have been detectable given their very low frequency.
Notably, a recent study from the PAGE consortium
included CRP as an exemplary quantitative trait, with
data from 8,349 African Americans with CRP, genotyped
on the Multi-Ethnic Genotyping Array (MEGA) and
imputed to 1000 Genomes Phase 3. Neither variant was
observed to be associated with CRP, despite detailed exam-
ination of secondary signals in a larger pooled sample size
than available here for African Americans (and in a sample
including some of the same African American partici-
pants, notably from WHI, as in our discovery and replica-
tion cohorts). This suggests that the use of a genotyping
array developed to more equitably capture global genetic
variation and subsequent imputation to the 1000 Ge-
nomes reference panel may still miss some population-
specific variant associations that can be identified using
WGS. In WHI our CRP-associated variants can be well
imputed using TOPMed as a reference panel (imputation
quality r2 R 0.9); the TOPMed reference panel has
203 larger sample size than 1000 Genomes Phase 3,
and increased imputation quality is expected in African
Americans based on previous work.39 Imputation quality
is only modestly attenuated in WHI using 1000 Genomes
Figure 2. Regulatory Role of Low-Frequency, African Ancestry-Specific Variant rs181704186
(A) Boxplot of natural log-transformed CRP values by allele for rs181704186 (for 23,157 major allele homozygotes, 119 heterozygotes,
and 3 minor allele homozygotes).
(B) Genome browser plot for rs181704186, chromHMM annotation in adult liver (yellow, enhancer; yellow, enhancer; red, transcription
start site) from RoadMap Epigenomics, H3K4me1 signal from adult liver, 100 vertebrates basewise conservation by PhyloP, transcription
factor ChIP-seq clusters from ENCODE (161 factor version, motifs highlighted in green, proportion cell types detected/total number of
cell types assayed displayed). We also display GeneHancer’s connection of the region containing this variant to CRP. No other variants
have linkage disequilibrium r2 R 0.8 with lead variant rs181704186.
(C) Luciferase assay demonstrating reduced transcriptional activity for the G allele, which is also associated with lower CRP levels. Blue
lines indicate the groups compared for each listed p value.
(D) Disrupted CEBPB transcription factor binding motif position weight matrix from Kheradpour and Kellis30 (CEBPB-disc1, with blue
box highlighting position changed by rs181704186).
(E) Differential protein binding for A and G allele in EMSA assay. EMSA with biotin-labeled probes containing the A or G allele of
rs181704186 shows an allele-specific band (lane 2 versus 7, indicated with red arrows) that is competed away by 40-fold excess of un-
labeled probe containing the A allele (lane 3), but unaffected by a 40-fold excess of probe containing the G allele (lane 4). Incubation
with an antibody targeting CEBPB partially disrupts the A-allele-specific protein-DNA complex (lane 5). NE, nuclear extract.
(F) Summary of direction of effect of rs181704186-G.Phase 3 as a reference panel (imputation quality r2 R
0.75), but this still leads to weaker association for
rs11265259 in particular using 1000 Genomes imputa-
tion, likely due to a reduction in effective sample size
(product of sample size and r2). Concurrent association
analysis in both sequenced and imputed data (using
the largest relevant sequencing dataset, such as TOPMed,
as a reference panel) may be a powerful strategy for
discovering low-frequency and rare variant associations
with many complex traits, particularly in non-European
populations.39Our results using WGS and replicated with TOPMed
imputed data exemplify the value of WGS in individuals
of diverse genetic ancestry. Despite having only 10% of
the sample size of the largest European GWAS meta-anal-
ysis to date, the genetic diversity and accurate genotype
calls for low frequency and rare variants in our multi-
ancestry study afforded us the ability to detect additional
population-specific association signals, including a low-
frequency variant with a large effect size. These association
signals add to our knowledge of the extensive allelic het-
erogeneity and diversity of the CRP genomic region, which
contains a number of shared and population-specific cod-
ing and regulatory alleles.10,12,28 Ultimately, finer dissec-
tion of the functional alleles at the CRP locus may have
consequences for understanding the biology of acute or
chronic inflammation or the causal role of CRP in inflam-
mation-related complex disorders. To determine whether
the two replicated African-specific CRP-associated variants
(rs11265259 and rs181704186) have downstream clinical
consequences, we performed a phenome-wide association
study (pheWAS) in the BioVU biobank. No phenotype as-
sociations were statistically significant at a Bonferroni
adjusted level. Though this result may be a consequence
of small sample size or sub-optimal imputation quality, it
is largely consistent with previous studies that have failed
to find a large number of clinical outcomes that correlate
with CRP-associated variants.12
A primary goal of many human genetics studies is to
identify the causal allele that underlies the association
with a human trait or disease. As such, the value of
deep sequencing data on hundreds of thousands of indi-
viduals from diverse genetic backgrounds should not be
understated. Our results demonstrate the potential for
WGS analysis to discover genetic signals, including
conditionally distinct, low-frequency signals at known
loci. Limitations of our current analysis include the
modest sample size, particularly for ancestry groups
other than European and African Americans, and the
focus on single-variant tests only. As larger sample sizes
become available, further study of aggregate tests for
very rare variants and structural variation is warranted.
Future studies from TOPMed and other large WGS efforts
integrating both sequencing data and dense imputation,
along with interrogation of rich functional annotation
databases and higher-throughput cellular assays, will
continue to clarify the role of genetic variation on com-
plex traits.Supplemental Data
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